Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease

Annals of Neurology

Volumn 76, Issue 2, 2014, Pages 223-230

  Fortea, Juan ^a,b   Vilaplana, Eduard ^a,b   Alcolea, Daniel ^a,b   Carmona Iragui, María ^a,b   Sánchez Saudinos, María Belén ^a,b   Sala, Isabel ^a,b   Antón Aguirre, Sofía ^a,b   González, Sofía ^c   Medrano, Santiago ^c   Pegueroles, Jordi ^a,b   Morenas, Estrella ^a,b   Clarimón, Jordi ^a,b   Blesa, Rafael ^a,b   Lleó, Alberto ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); FEMALE; FOLLOW UP; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; ATROPHY; BRAIN CORTEX; CROSS-SECTIONAL STUDY; PATHOLOGY; PRODROMAL SYMPTOM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATROPHY; BIOLOGICAL MARKERS; CEREBRAL CORTEX; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS; PRODROMAL SYMPTOMS; TAU PROTEINS;

EID: 84907597440     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24186     Document Type: Article

References (40)

1. Sperling R, Aisen P, Beckett L,. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292.
2. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-216.
3. Knopman DS, Jack CR, Wiste HJ, et al. Brain Injury Biomarkers are not dependent on ß-Amyloid in Normal Elderly. Ann Neurol 2013; 73: 472-480.
4. Chételat G,. Alzheimer disease: Aβ-independent processes-rethinking preclinical AD. Nat Rev Neurol 2013; 9: 123-124.
5. Becker J, Hedden T, Carmasin J,. Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol 2011; 69: 1032-1042.
6. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009; 19: 497-510.
7. Storandt M, Mintun MA, Head D, et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-β peptide deposition identified with Pittsburgh compound B. Arch Neurol 2010; 66: 1476-1481.
8. Fagan A, Head D, Shah A,. Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009; 65: 176-183.
9. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex 2010; 20: 2069-2079.
10. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2008; 132 (pt 5): 1310-1323.
11. Josephs KA, Whitwell JL, Ahmed Z, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 2008; 63: 204-212.
12. Chételat G, Villemagne VL, Pike KE, et al. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010; 133: 3349-3358.
13. Johnson SC, Christian BT, Okonkwo OC, et al. Amyloid burden and neural function in people at risk for Alzheimer's disease. Neurobiol Aging 2014; 35: 576-584.
14. Fjell A, McEvoy L, Holland D,. Brain changes in older adults at very low risk for Alzheimer's disease. J Neurosci 2013; 33: 8237-8242.
15. Fortea J, Sala-Llonch R, Bartrés-Faz D, et al. Cognitively preserved subjects with transitional cerebrospinal fluid β-amyloid 1-42 values have thicker cortex in Alzheimer disease vulnerable areas. Biol Psychiatry 2011; 70: 183-190.
16. Desikan RS, McEvoy LK, Thompson WK, et al. Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol 2011; 70: 657-661.
17. Desikan RS, McEvoy LK, Thompson WK, et al. Amyloid-β-associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol 2012; 69: 709-713.
18. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol 2009; 65: 403-413.
19. Fischl B, Dale AM,. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 2000; 97: 11050-11055.
20. Fortea J, Sala-Llonch R, Bartrés-Faz D, et al. Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. J Alzheimers Dis 2010; 22: 909-922.
21. Espeseth T, Westlye LT, Fjell AM, et al. Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. Neurobiol Aging 2008; 29: 329-340.
22. Espeseth T, Westlye LTL, Walhovd KB, et al. Apolipoprotein E ε4-related thickening of the cerebral cortex modulates selective attention. Neurobiol Aging 2012; 33: 304.e1-322.e1.
23. Riudavets MA, Iacono D, Resnick SM, et al. Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. Neurobiol Aging 2007; 28: 1484-1492.
24. West MJ, Bach G, Søderman A, Jensen JL,. Synaptic contact number and size in stratum radiatum CA1 of APP/PS1DeltaE9 transgenic mice. Neurobiol Aging 2009; 30: 1756-1776.
25. Maheswaran S, Barjat H, Rueckert D, et al. Longitudinal regional brain volume changes quantified in normal aging and Alzheimer's APP x PS1 mice using MRI. Brain Res 2009; 1270: 19-32.
26. Spillantini MG, Goedert M,. Tau pathology and neurodegeneration. Lancet Neurol 2013; 12: 609-622.
27. Braak H, Braak E,. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18: 351-357.
28. Price JL, McKeel DW, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009; 30: 1026-1036.
29. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-1491.
30. Hurtado DE, Molina-Porcel L, Iba M, et al. Aβ accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 2010; 177: 1977-1988.
31. Khan UA, Liu L, Provenzano FA, et al. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci 2013; 17: 304-311.
32. Rapoport M, Dawson HN, Binder LI, et al. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 2002; 99: 6364-6369.
33. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316: 750-754.
34. Desikan RS, McEvoy LK, Holland D, et al. Apolipoprotein E ε4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease. AJNR Am J Neuroradiol 2013; 34: 505-510.
35. Vos S, Xiong C, Visser P,. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013; 12: 957-965.
36. Fox NC, Black RS, Gilman S, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64: 1563-1572.
37. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 311-321.
38. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370: 322-333.
39. Thal DR, Rüb U, Orantes M, Braak H,. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.
40. La Joie R, Perrotin A, Barré L, et al. Region-specific hierarchy between atrophy, hypometabolism, and βmyloid (Aβ) load in Alzheimer's disease dementia. J Neurosci 2012; 32: 16265-16273.